Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 8 of 24, showing 10 Applications out of 238 total, starting on record 71, ending on 80

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

71.

ECCT/20/09/02   BEe-HIVe
     B-ENHANCEMENT OF HBV VACCINATIONIN PERSONS LIVING WITH HIV (BEe-HIVe) EVALUATION OF HEPLISAV-B,A5379   
Principal Investigator(s)
1. JOSPHAT KOSGEI
Site(s) in Kenya
KEMRI/KERICHO CLINIC RESEARCH CENTRE
 
27-11-2020 View

72.

ECCT/19/12/02   VPM1002 Phase III PoI
    A multicenter, Phase III double blind, randomized active controlled study to evaluate efficacy and safety of VPM1002 in comparison with BCG in prevention of Mycobacterium tuberculosis infection in newborn infants.     
Principal Investigator(s)
1. Videlis Nduba
Site(s) in Kenya
1. KEMRI-CRDR Nairobi (Nairobi City county)
2. KEMRI-CRDR Siaya (Siaya county)
 
20-04-2020 View

73.

ECCT/25/08/02   MK-8527-010
    A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women.   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
Site(s) in Kenya
1. KEMRI CMR RCTP (Kisumu county)
 
21-11-2025 View

74.

ECCT/15/02/03   IVERMAL study
    Efficacy and safety of high-dose Ivermectin for reducing malaria transmission: A dose finding study   
Principal Investigator(s)
1. Menno Roderick Smit
Site(s) in Kenya
1. Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH) (Kisumu county)
2. Kisumu District Hospital (KDH), (Kisumu county)
3. Siaya District Hospital (Siaya county)
4. Vihiga District Hospital (Vihiga county)
 
26-03-2015 View

75.

ECCT/23/04/05   BiMVaC01
    A randomised, controlled clinical trial to assess and compare the immunogenicity, safety and reactogenicity of the bivalent Omicron BA.4/BA.5 adapted, and the original Wuhan-Hu-1-strain, BNT162b2 COVID-19 vaccine formulations in healthy unvaccinated East African adults.   
Principal Investigator(s)
1. NDUNGU FRANCIS
2. Said Jongo
Site(s) in Kenya
KEMRI-CGMRC Kilifi
 
06-07-2023 View

76.

ECCT/25/06/01   Neosep1
    An open-label randomised controlled trial comparing novel combination and currently used antibiotic regimens for the empiric treatment of neonatal sepsis with a run-in confirmatory pharmacokinetic phase.   
Principal Investigator(s)
1. Christine Nafula Manyasi
Site(s) in Kenya
1. Mbagathi County Referral Hospital (Nairobi City county)
 
02-10-2025 View

77.

ECCT/25/06/02   Neosep1
    An open-label randomised controlled trial comparing novel combination and currently used antibiotic regimens for the empiric treatment of neonatal sepsis with a run-in confirmatory pharmacokinetic phase.   
Principal Investigator(s)
1. Nayirat Mohamed Dormohamed
Site(s) in Kenya
1. Coast General Teaching and Referral Hospital (Mombasa county)
 
02-10-2025 View

78.

ECCT/22/10/05   Agios Study
    A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. Mitapivat - AG348-C-020   
Principal Investigator(s)
1. Videlis N Nduba
Site(s) in Kenya
1. KEMRI/CRDR (Nairobi City county)
2. KEMRI Siaya Clinical Research Annex (Siaya county)
 
26-02-2023 View

79.

ECCT/23/09/03   CONSTELLATION
    A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants   
Principal Investigator(s)
1. Dr Simon Kariuki
Site(s) in Kenya
1. Kenya Medical Research Institute- Centre for Global Health Research (Kisumu county)
 
19-12-2023 View

80.

ECCT/24/04/08   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Wilson Muraya
Site(s) in Kenya
1. KEMRI Mtwapa Clinical Research Site- Kilifi (Kilifi county)
 
08-05-2024 View